Abstract This Consensus Statement from an international, multidisciplinary workshop
sponsored by the Pituitary Society offers evidence-based graded consensus …

Aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs) are heterogeneous with
regard to clinical presentation, proliferative markers, clinical course, and response to …

The tumor microenvironment (TME), the complex environment in which tumors develop, has
been increasingly targeted for cancer treatment in recent years. Aggressive pituitary tumors …

After temozolomide failure, no evidence-based treatment option is currently available for
aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs). Moreover, once …

Purpose Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs) and
application of current immunotherapy for refractory PitNETs remains debated. We aim to …

The pituitary tumour microenvironment encompasses a spectrum of non-tumoural cells, such
as immune, stromal or endothelial cells, as well as enzymes and signalling peptides like …

Simple Summary The biological behavior of Pituitary Neuroendocrine Tumors (PitNET)
remains unclear. Many efforts have been performed in order to clarify this point. The …

Purpose The purpose of this work was toinvestigate the clinicopathological characteristics at
the initial diagnosis of the pituitary tumor and at pituitary carcinoma (PC) diagnosis …

Prolactinomas are the most common functional pituitary tumors, accounting for 40% of all
pituitary adenomas. Medical treatment with dopamine agonists (DA), mainly cabergoline, is …

A small subset of lactotroph adenomas is resistant to dopamine agonists (DA) and can also
demonstrate aggressive or even malignant behavior. The implicated mechanisms are not …